NCT06354465

Injectable Extended-Release Buprenorphine (XR-B) in a Correctional Setting: Qualitative Interviews

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 25 (estimated)
• Sponsor: Lifespan · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

This qualitative study investigates the potential benefits and challenges of using a once-a-month injectable medication, known as extended-release buprenorphine (XR-B), to treat individuals with opioid use disorder (OUD) within a correctional setting. The research aims to understand if XR-B can be a feasible and effective alternative to the standard daily treatment and to identify which groups within the prison population may benefit the most from this treatment. In-depth interviews are conducted with incarcerated individuals and relevant stakeholders.

Conditions

• Opioid Use Disorder
• Criminal Justice
• Treatment Adherence and Compliance

Timeline

• Start date: 2023-07-01
• Primary completion: 2024-07-01
• Completion: 2024-07-01
• First posted: 2024-04-09
• Last updated: 2024-04-09

Locations

1 site across 1 country: United States